Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018146641) NOVEL INHIBITORS OF CELLULAR SIGNALLING
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/146641 International Application No.: PCT/IB2018/050839
Publication Date: 16.08.2018 International Filing Date: 12.02.2018
IPC:
C07D 417/12 (2006.01) ,C07J 9/00 (2006.01) ,A61K 47/28 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
J
STEROIDS
9
Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
28
Steroids
Applicants:
INVICTUS ONCOLOGY PVT. LTD. [IN/IN]; Plot 465, F.I.E, Patparganj Industrial Area Delhi 110092, IN
Inventors:
ROY, Monideepa; US
BISWAS, Goutam; IN
SURYAVANSHI, Hemant; IN
MUKHERJEE, Anubhab; IN
Agent:
KASETTI, Yoganjaneyulu; IN
BHOLA, Ravi; IN
MUKHARYA, Durgesh; IN
RANGANATH, Shivakumar; IN
J., Vikas; IN
RAJAGOPAL, Lakshmi; IN
CHOTIA, Meenakshi; IN
R, Sridhar; IN
Priority Data:
20171100497911.02.2017IN
Title (EN) NOVEL INHIBITORS OF CELLULAR SIGNALLING
(FR) NOUVEAUX INHIBITEURS DE SIGNALISATION CELLULAIRE
Abstract:
(EN) The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula I, compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors of BLZ-945-lipids conjugates, GW2580-lipid conjugates and PLX-3397-lipid conjugates demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof.
(FR) La présente invention concerne de manière générale des inhibiteurs de signalisation cellulaire du composé de formule I, des compositions et des préparations les comprenant, des procédés, des processus et des utilisations associés. La présente invention concerne particulièrement, des inhibiteurs CSF-IR de conjugués BLZ-945-lipides, de conjugués GW2580-lipide et de conjugués PLX-3397-lipide présentant une inhibition prolongée de la voie de signalisation CSF/CSFIR avec une toxicité réduite. La présente invention concerne également des agents thérapeutiques combinatoires supramoléculaires, un inhibiteur CSF-IR étant combiné à un ou plusieurs parmi, un agent chimiothérapique, un inhibiteur de kinase et un immunorégulateur, chacun d'entre eux étant éventuellement conjugué avec un lipide. La présente invention concerne également un procédé de traitement du cancer, des allergies, du lupus érythémateux systémique, de la néphrite, de la bronchopneumopathie chronique obstructive, et des fonctions macrophages anormales ou toute combinaison de ceux-ci.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)